• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Cephalon

Related Topics

  1. Kinetic Concepts
  2. Teva Pharmaceutical Industries
  3. Thermo Fisher Scientific
  4. American Greetings
  5. Gen-Probe
  6. Bio-Rad Laboratories

Popular Topics

  1. Frontline
  2. Investment Banking
  3. Aberdeen Asia-Pacific Income Fund
  4. Ross Systems
  5. Canterbury Consulting Group

Cephalon

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. Cephalon , Inc . CEPH Q4 2010 Earnings Call Transcript

    Good afternoon, everyone and welcome to the Cephalon Fourth Quarter and Full Year 2010 Earnings Conference Call. Today's call is being recorded. At this time, for opening remarks and introductions I would like to turn the call over to Mr. Chip Merritt, Vice President of Investor Relations. Please ...

  2. Cephalon , Inc . CEPH Q2 2010 Earnings Call Transcript

    Good day, everyone and welcome to the Cephalon Second Quarter 2010 Earnings Conference Call. Today's call is being recorded.

  3. Cephalon , Inc . CEPH Q1 2010 Earnings Call Transcript

    Good day, everyone, and welcome to the Cephalon First Quarter 2010 Earnings Conference Call. Today s call is being recorded. At this time, for opening remarks and introductions, I would like to turn the call over to Mr. Chip Merritt, Vice President of Investor Relations. Please go ahead, sir.

  4. Cephalon , Inc . CEPH Q4 2009 Earnings Call Transcript

    Good day, everyone, and welcome to the Cephalon s Fourth Quarter 2009 Earnings Conference Call. Today s call is being recorded. At this time, for opening remarks and introductions, I would like to turn the call over to Mr. Chip Merritt, Vice President of Investor relations. Please go ahead, sir.

  5. Cephalon , Inc . CEPH Q3 2010 Earnings Call Transcript

    Good day, everyone, and welcome to the Cephalon Third Quarter 2010 Earnings Conference Call. Today's call is being recorded. At this time, for opening remarks and introductions I would like to turn the call over to Mr. Chip Merritt, Vice President of Investor Relations. Please go ahead, sir.

  6. Research and Markets: Cephalon Partnering 2005-2013

    Research and Markets: Cephalon Partnering 2005-2013

  7. Why Retirement Funds Fall Short

    Cephalon CEPH announced Monday that Gabitril did not meet the primary endpoints in a Phase III study for generalized anxiety disorder (GAD). We're sticking with our fair value estimate of $44 per share, as we had assumed only a modest increase in Gabitril sales from this additional indication. ...

  8. Top Biotech Acquisition Candidates

    2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.

  9. Finding Good Pharma Stocks

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  10. Our Outlook for Health-Care Stocks

    While we remain bullish on the sector, health-care growth depends on the economy.

Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.